Integra LifeSciences Holdings Corp. (IART) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Globus Medical, Inc.

Sotera Health Co.

Haemonetics Corp.

Merit Medical Systems, Inc.

Envista Holdings Corp.

Glaukos Corp.

Sanmina Corp.

Neogen Corp.

Lantheus Holdings, Inc.

Integra LifeSciences Holdings Corp.

Inari Medical, Inc.

Why is Integra LifeSciences Holdings Corp. ?

Poor long term growth as Operating profit has grown by an annual rate -4.35% of over the last 5 years

Negative results in Sep 25

OPERATING CASH FLOW(Y) Lowest at USD 89.31 MM
PRE-TAX PROFIT(Q) At USD 7.94 MM has Fallen at -68.05%
NET PROFIT(Q) At USD 9.36 MM has Fallen at -72.89%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -57.86%, its profits have risen by 28.6% ; the PEG ratio of the company is 0.2

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -0.98% over the previous quarter and currently hold 0.05% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -57.86% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Integra LifeSciences Holdings Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Integra LifeSciences Holdings Corp.

-57.82%

-1.11

61.83%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.57%

EBIT Growth (5y)

-4.35%

EBIT to Interest (avg)

5.10

Debt to EBITDA (avg)

3.74

Net Debt to Equity (avg)

1.04

Sales to Capital Employed (avg)

0.50

Tax Ratio

32.73%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

7.88%

ROE (avg)

10.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.72

EV to EBIT

14.65

EV to EBITDA

7.51

EV to Capital Employed

0.89

EV to Sales

1.41

PEG Ratio

0.21

Dividend Yield

ROCE (Latest)

6.07%

ROE (Latest)

11.65%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.11% (YoY

-17What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 89.31 MM

PRE-TAX PROFIT(Q)

At USD 7.94 MM has Fallen at -68.05%

NET PROFIT(Q)

At USD 9.36 MM has Fallen at -72.89%

ROCE(HY)

Lowest at -38.71%

CASH AND EQV(HY)

Lowest at USD 521.49 MM

DEBT-EQUITY RATIO (HY)

Highest at 167.5 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.57 times

INTEREST(Q)

Highest at USD 27.35 MM

Here's what is working for Integra LifeSciences Holdings Corp.

Raw Material Cost

Fallen by 0.11% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 38.42 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Integra LifeSciences Holdings Corp.

Pre-Tax Profit

At USD 7.94 MM has Fallen at -68.05%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 9.36 MM has Fallen at -72.89%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD 89.31 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

At USD 27.35 MM has Grown at 21.7%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest

Highest at USD 27.35 MM

in the last five periods and Increased by 21.7% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 521.49 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 167.5 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.57 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio